Adverum begins Phase I/II of ADVM-043 for AAT deficiency

Adverum Biotechnologies Inc. (NASDAQ:ADVM) began the Phase I/II ADVANCE trial to evaluate ADVM-043 in up to 20 patients with alpha-1 antitrypsin (AAT; A1AT; SERPINA1) deficiency.

The study will enroll up to four cohorts, with the first three receiving escalating doses of IV ADVM-043. Adverum said the fourth cohort may receive intrapleural ADVM-043...